Eyenovia announces $12 million registered direct offering

New york, aug. 24, 2023 (globe newswire) -- eyenovia, inc. (nasdaq: eyen), a commercial-stage ophthalmic technology company commercializing mydcombi™ (tropicamide+phenylephrine ophthalmic spray for mydriasis) and developing the optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced that it has entered into a securities purchase agreement with a leading health care investor in an offering of 4,198,633 shares of its common stock, pre-funded warrants to purchase up to 2,252,979 shares of common stock and warrants to purchase up to 4,838,709 shares of common stock (the "offering"). the combined offering price for each share of common stock and accompanying warrant is $1.86, and the offering price for each pre-funded warrant and accompanying warrant is $1.85.
EYEN Ratings Summary
EYEN Quant Ranking